Intermittent in Biological Technology
Navigation Links
Intermittent in Biological Technology
... because atrial fibrillation (AF), a common cardiac
arrythmia, is often intermittent and therefore under diagnosed. Detecting
AF frequently requires more ... to estimate that 20-30% of these subtypes is
likely due to undiagnosed, intermittent AF. This means that AF causes an
even larger proportion of stroke than ...
... AEterna Zentaris. This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing ...
... drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for ...
... study (041) titled, "Cetrorelix pamoate in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study", will assess an intermittent dosage regimen of cetrorelix pamoate as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... 2008, the company commenced a Phase I/II dose-range-finding, safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent claudication. In early 2009, the company will initiate a Phase I proof-of-mechanism trial in patients with high-grade glioma at Johns Hopkins ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... The unique activity profile of 2NTX-99 suggests potential utility in a range of atherosclerotic, thrombotic, and microvascular diseases, including intermittent claudication, diabetic nephropathy and pulmonary arterial hypertension. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage ...
... and the medical community about blood management as a way to improve the efficiency and quality of care simultaneously." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
... with our mission to provide the best possible service to our client hospitals and optimal outcomes for their patients." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
... pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", involves approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
... a short course therapy with cetrorelix. The improvement lasted well beyond the dosing period. This should, therefore, allow for the development of intermittent dosage regimens of cetrorelix with two or three treatment courses per year, thus relieving concerns about treatment compliance with drugs requiring ...
... two formulations of cetrorelix to determine the extent and duration of symptomatic improvement and to select the interval between courses for an intermittent treatment scheme. Trial Design Trial-A compared 3 regimens of subcutaneous cetrorelix acetate with placebo (35 patients/group): 5mg x 4, 7 days ...
... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
... for revenue recognition have now been met. Also includes a $200,000 fee paid by Hollister for marketing rights to our hydorphilic intermittent catheter in September 2003. The fee paid by Hollister was fully recognized in December 2006. This adjustment reduces net income related ...
... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... higher than the estimated efficacious human dose. Clinical trials will begin in 2008 in peripheral vascular disease patients suffering from intermittent claudication and in cancer patients undergoing radiation therapy. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, ...
... AEterna Zentaris. This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing ...
... drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for ...
New Report Just Published: World Prostate Cancer Therapeutics Market Report
... of Orchiectomy II-35 Time to Start Hormonal Therapy II-35 Strategies to Enhance Hormonal Treatment II-36 Combination Therapy II-36 intermittent Therapy II-36 Radiation Therapy II-36 Brachytherapy II-36 Treatment Procedure II-37 Benefits of Brachytherapy II-38 Drawbacks of ...... study (041) titled, "Cetrorelix pamoate in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study", will assess an intermittent dosage regimen of cetrorelix pamoate as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... 2008, the company commenced a Phase I/II dose-range-finding, safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent claudication. In early 2009, the company will initiate a Phase I proof-of-mechanism trial in patients with high-grade glioma at Johns Hopkins ...
Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... The unique activity profile of 2NTX-99 suggests potential utility in a range of atherosclerotic, thrombotic, and microvascular diseases, including intermittent claudication, diabetic nephropathy and pulmonary arterial hypertension. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage ...
AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
... combination products." AcelRx Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions, with an initial emphasis on pain management. ...New small-scale generator produces alternating current by stretching zinc oxide wires
... Nanotechnology Excellence. Earlier nanowire nanogenerators and microfiber nanogenerators developed by Wang and his research team depended on intermittent contact between vertically-grown zinc oxide nanowires and an electrode, or the mechanical scrubbing of nanowire-covered fibers. These devices were ...... and the medical community about blood management as a way to improve the efficiency and quality of care simultaneously." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
Alexion Reports Third Quarter 2008 Results
... recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis. About Alexion Alexion ...... with our mission to provide the best possible service to our client hospitals and optimal outcomes for their patients." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
... pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", involves approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...
Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
... facilities and provide data on its impact on patient care. "Current methods for measuring total hemoglobin are invasive and only offer delayed and intermittent results," stated Joe E. Kiani, Masimo Chairman and CEO. "We look forward to working closely with the first customers of our noninvasive hemoglobin ...Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...Derma Sciences Reports Second Quarter 2008 Results
... ahead. XTRASORB(TM), our new super-absorbent dressing (which complements the MEDIHONEY products) is due out in September, MOBILITY1(TM), our portable intermittent compression device, will be available in October, and we are in the final phase of preparing to launch a novel off-loading device for diabetic foot ...... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
... crystals in and around the connective tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options, and ...Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...... a short course therapy with cetrorelix. The improvement lasted well beyond the dosing period. This should, therefore, allow for the development of intermittent dosage regimens of cetrorelix with two or three treatment courses per year, thus relieving concerns about treatment compliance with drugs requiring ...
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...... two formulations of cetrorelix to determine the extent and duration of symptomatic improvement and to select the interval between courses for an intermittent treatment scheme. Trial Design Trial-A compared 3 regimens of subcutaneous cetrorelix acetate with placebo (35 patients/group): 5mg x 4, 7 days ...
Alexion Reports First Quarter 2008 Results
... recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis. About Alexion ...... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
... in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", will involve approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...Amsterdam Molecular Therapeutics Reports Full Year Results 2007
... - Pre-registration trial in Canada on track - Appointment of Ferdinand Verdonck as chairman of supervisory board. - Global rights for acute intermittent porphyria treatment - Exclusive license to all gene therapy products from CIMA - Agreement with CIMA/Digna Biotech for AAV-mediated IGF-I ...... for revenue recognition have now been met. Also includes a $200,000 fee paid by Hollister for marketing rights to our hydorphilic intermittent catheter in September 2003. The fee paid by Hollister was fully recognized in December 2006. This adjustment reduces net income related ...
Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
... Alexza is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...... higher than the estimated efficacious human dose. Clinical trials will begin in 2008 in peripheral vascular disease patients suffering from intermittent claudication and in cancer patients undergoing radiation therapy. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, ...
Alexza Elects Dr. Hal V. Barron to Its Board of Directors
... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...Other ContentsgonadgonococcalglycosylatedglycosylatedgroingroingonorrheagonorrheabumpsbumpsbumpsbumpsOther TagsTWARTWARTWARTWARTWARpneumoniaeOther Tagsattendance 2developing 2developing 3developing 4developing 5developing 6developing 7developing 8developing 9developing 10time 2time 3time 4time 5time 6time 7time 8time 9time 10real 2real 3real 4real 5real 6real 7real 8real 9real 10seeking 2seeking 3seeking 4seeking 5transform 2transform 3transform 4
(Date:11/25/2009)...ters, police officers and ambulance workers faced ...er complex. They battled to save people from the c...kled fires and evacuated as many people as they co... people. And making their jobs even harder was the...s and their relatives jammed mobile networks with ...
(Date:11/25/2009)...t may be just as vital to your health as what you ...iological Studies. Their experiments in mice revea...of genes in the liverthe body,s metabolic clearing...y the body,s circadian clock as conventional wisdo...ivity of a large number of genes completely indepe...
(Date:11/24/2009)... and flabby arteries from collapsing have been tru...are no longer needed -- once the arteries are stre...tors had no choice but to leave them in place. , ...epartment of Biomedical Engineering has developed ...rugs where they,re needed, then dissolves. , "Ou...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 1PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 2PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 3PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 4PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 5PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 6PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 7PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 8PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 9PRO DEX INC Announces Fiscal First Quarter 2010 Profit Update on Business Development Activities and Renewal of Banking Agreement 5843 10Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded 5839 1Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded 5839 2U M study uncovers key to how triggering event in cancer occurs 60341 1U M study uncovers key to how triggering event in cancer occurs 60341 2(Date:11/27/2009)...RNewswire/ -- Allrecipes.com , the world,s #1 f...c numbers, with more than 2.8 million visitors the...e of what was served on the biggest food holiday o...weighed in at 2,225 calories per serving, a 5 perc...the Allrecipes site, Sweet Potato Pie I stole th...
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)...ire/ -- The diabetes population in the United Stat...nnual medical spending on the disease is projected...according to a study published in the December iss...betes ® Program (NCDP), a program of Novo Nor... University of Chicago. ,, According to the for...
(Date:11/26/2009)... strains or worse , , THURSDAY, Nov. 26 ...h stuffing your turkey full to bursting, but you m...ase as you pack for holiday trips. , More than ...l emergency rooms, doctors, offices, clinics and o...es, such as muscle strains, pulls and tears, accor...
(Date:11/26/2009)...Live Life Again Center, a practice offering weigh...ber of physicians who are taking advantage of pop...iduals who are interested in surgical weight loss ...izing Facebook to share before-and-after photos an...y. , Dallas, TX (Vocus) N...
Breaking Medicine News(10 mins):Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3[0] It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows[3] Pack Right for the Holidays to Avoid the ER[1] Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |